It is time to stand up and support the many heroes in this battle.
Last week, I was asked by John Mappin if I would fly into London to help support the honorable Andrew Bridgen, MP in his quest to clear his name and to help spread the word about the censorship and barriers to free speech which he has encountered while trying to help alert the public to the adverse events associated with the vaccine.
Jill and I immediately decided that this was a trip worth taking.
Brian Rose of âLondon Realâ heard that I would be coming to town and asked for a sit-down interview. I consider him a friend and fellow truth warrior, and I had the time directly after landing, and so was glad to enthusiastically agree.
Andrew Bridgen Destroys the Vaccine narrative in UK Parliament.
[All the MPs that walked out are showing they are not interested in protecting their constituents; they're only interested in harming them for financial gain. Gibraltar's MPs?]
If you are ever in doubt about why the rats in parliament scuttled away during Bridgen's speech yesterday. From 2021............
"Drug companies are giving groups of MPs and peers that campaign on health issues hundreds of thousands of pounds a year in âhiddenâ funding that could hand them âundue influenceâ, research has found".
"The pharmaceutical industry has built up a âhidden web of policy influenceâ over dozens of all-party parliamentary groups (APPGs) at Westminster by making hundreds of ânon-transparentâ payments to them, as part of the industryâs wider effort to lobby those in power, researchers claim".
"Fifty-eight APPGs focusing on different aspects of health received 468 payments totalling just under ÂŁ2.2m in direct and indirect funding from pharmaceutical firms between 2012 and 2018, academics from the University of Bath found. APPGs receive no money from parliament to support their activities, which often involve ministers being questioned and being sent reports."
"In the context of health-related APPGs, payments from the pharmaceutical industry represent institutional conflicts of interest as they create circumstances where the primary interest, policymaking in the interests of public health, is at risk of being unduly influenced by the secondary interest, the pharmaceutical industryâs goal of maximising profitsâ, the authors conclude, in a paper published on Thursday evening in the medical journal PLOS One".
